Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | NSD2 | O96028 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9431194 | 0.96 | MAPT (0.67) | NPSR1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL7864977 | 0.95 | MAPT (0.66) | NPSR1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL7857190 | 0.95 | MAPT (0.66) | NPSR1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL7867868 | 0.95 | MAPT (0.66) | NPSR1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL3542412 | 0.88 | LMNA (0.72) | NPSR1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL10760288 | 0.86 | LMNA (0.66) | NPSR1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL944312 | 0.85 | POLB (0.72) | MAPTALDH1A1KDM4ENSD2ABL1 | |
| SCHEMBL20545268 | 0.83 | LMNA (0.65) | NPSR1LMNAMAPTKDM4ENPC1 | |
| SCHEMBL5267033 | 0.83 | HRH4 (0.54) | NPSR1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL10760234 | 0.83 | MAPT (0.60) | NPSR1LMNAMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1249450-B1 | BENZIMIDAZOLE DERIVATIVES AS HUMAN CHYMASE INHIBITORS | TEIJIN PHARMA LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| US-20040162311-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2004-08-19 | — | — | US | disclosed |
| US-20040010004-A1 | Benzimidazole derivatives | TEIJIN LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20030083315-A1 | Human chymase inhibitors | TEIJIN LIMITED (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1249450-A1 | BENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2002-10-16 | — | — | EP | disclosed |
| EP-1167360-A9 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1167360-A1 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5128359-A | Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation | LABORATOIRES UPSA (FR) | 1992-07-07 | — | — | US | disclosed |
| US-5124336-A | Cardiovascular disorders | LABORATOIRES UPSA (FR) | 1992-06-23 | — | — | US | disclosed |
| US-5021443-A | Noval benzimidazole and azabenzimiazole derivatives which are thromboxane receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present | LABORATOIRES UPSA (FR) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162311-A1 | Benzimidazole derivative | CMA1, CBR3, CBR1 | NPSR1 1118/4885LMNA 1813/4885MAPT 4120/4885 |
| US-20030083315-A1 | Human chymase inhibitors | CMA1, CTRL, CPA4 | NPSR1 974/4885LMNA 2529/4885MAPT 3505/4885 |
| US-20040010004-A1 | Benzimidazole derivatives | CMA1, CBR3, CBR1 | NPSR1 1099/4885LMNA 1790/4885MAPT 4101/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | NPSR1 4118/4885LMNA 3900/4885MAPT 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.